Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome

Kim, Jae Min; Chang, Young Suk; Kim, Jong Woo; Kim, Chul Gu; Lee, Jun Young

doi:10.3341/kjo.2016.0026

Cited by 4 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 34 included studies, 24 reported on anti-VEGF therapy alone ( Engelbert et al, 2009 ; Montero et al, 2009 ; Atmani et al, 2010 ; Hemeida et al, 2010 ; Reche-Frutos et al, 2011 ; Parodi et al, 2013 ; Gharbiya et al, 2014 ; Inoue et al, 2014 ; Shin and Yu, 2014 ; Park and Roh, 2015 ; Cho et al, 2016 ; Matsumoto et al, 2016 ; Kim et al, 2017a ; Kim et al, 2017b ; Hata et al, 2017 ; Kim et al, 2018 ; Browning et al, 2019 ; Invernizzi et al, 2019 ; Kim et al, 2019 ; Maruyama-Inoue et al, 2019 ; Arias et al, 2020 ; Ernest et al, 2020 ; Kim, 2020 ; Kim et al, 2020 ), 8 reported on anti-VEGF therapy combined with PDT ( Saito et al, 2010 ; Lee et al, 2011 ; Nakano et al, 2012 ; Saito et al, 2012 ; Saito et al, 2013 ; Seidel et al, 2013 ; Saito et al, 2016 ; Malamos et al, 2018 ) and 2 studies compared anti-VEGF therapy alone versus combined with PDT. ( Rouvas et al, 2012 ; Arias et al, 2016 ).…”

Section: Resultsmentioning

confidence: 99%

Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis

et al. 2023

View full text Add to dashboard Cite

Purpose: To assess functional and anatomical outcomes of intravitreal anti-Vascular Endothelial Growth Factor (anti-VEGF) monotherapy versus combined with verteporfin Photodynamic Therapy (PDT) for Retinal Angiomatous Proliferation (RAP).Methods: Studies reporting outcomes of intravitreal anti-VEGF monotherapy and/or in combination with verteporfin PDT in RAP eyes with a follow-up ≥ 12 months were searched. The primary outcome was the mean change in best corrected visual acuity (BCVA) at 12 months. Mean change in central macular thickness (CMT) and mean number of injections were considered as secondary outcomes. The mean difference (MD) between pre- and post-treatment values was calculated along with 95% Confidence Interval (95% CI). Meta-regressions were performed to assess the influence of anti-VEGF number of injections on BCVA and CMT outcomes.Results: Thirty-four studies were included. A mean gain of 5.16 letters (95% CI = 3.30–7.01) and 10.38 letters (95% CI = 8.02–12.75) was shown in the anti-VEGF group and combined group, respectively (anti-VEGF group vs. combined group, p < 0.01). A mean CMT reduction of 132.45 µm (95% CI = from −154.99 to −109.90) and 213.93 µm (95% CI = from −280.04 to −147.83) was shown in the anti-VEGF group and combined group, respectively (anti-VEGF group vs. combined group, p < 0.02). A mean of 4.9 injections (95% CI = 4.2–5.6) and 2.8 injections (95% CI = 1.3–4.4) were administered over a 12-month period in the anti-VEGF group and combined group, respectively. Meta-regression analyses showed no influence of injection number on visual and CMT outcomes. High heterogeneity was found across studies for both functional and anatomical outcomes.Conclusion: A combined approach with anti-VEGF and PDT could provide better functional and anatomical outcomes in RAP eyes compared with anti-VEGF monotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Although it is important to treat the vascular and structural features related to the neovascularization to prevent further decline of visual function, there is no clear relation between the course of vascular or structural features and whether the visual acuity improves, stabilizes or deteriorates. Kim et al (2017) suggested that a poorer visual outcome is related to the presence of a PED at baseline. PED was present in almost all patients in our cohort (Table 2), showing an overall improved visual acuity (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…5). Kim et al (2017) treated patients with anti‐VEGF monotherapy, therefore combined therapy with PDT and IVB might be favourable when a PED is present at baseline.…”

Section: Discussionmentioning

confidence: 99%

Detailed optical coherence tomography angiographic short‐term response of type 3 neovascularization to combined treatment with photodynamic therapy and intravitreal bevacizumab

Smid

Vermeer

Wong

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose To explore the short‐term vascular and structural changes of type 3 neovascularization using optical coherence tomography angiography (OCT‐A) when treated with a combination of photodynamic therapy (PDT) and intravitreal bevacizumab (IVB), and to evaluate the course of different sequences of the combined therapies. Methods Thirty eyes of 29 treatment‐naïve patients with a type 3 neovascularization were included in this prospective observational cohort study. They were all treated with PDT and IVB 2 weeks apart, starting either with PDT (PDT‐first group) or IVB (IVB‐first group). Optical coherence tomography angiography (OCT‐A) imaging was performed at week 0, 2, 4 and 18, and best corrected visual acuity (BCVA) at week 0 and 18. Vascular, structural and functional features were graded and analysed over time. Results In all patients, at all follow‐up visits, vascular and structural features were significantly more often decreased or resolved than unchanged or increased. Best corrected visual acuity (BCVA) significantly improved at 18 weeks. Vascular, structural and functional outcomes were all slightly better in the PDT‐first group compared to the IVB‐first group, although not statistically significant. Conclusion Combined treatment of PDT and IVB is effective in short‐term for type 3 neovascularization based on vascular and structural features. Initial treatment with PDT tended to be more effective than with IVB.

show abstract

“…Whilst some studies have reported a non-significant difference in visual improvement between eyes with or without SRF [ 34 , 49 ], others report SRF (Fig. 2C ) is in fact associated with superior baseline and outcome BCVA [ 32 , 38 , 47 , 50 , 51 ] and considered a significant predictor of BCVA gains at 12 months, but only when combined with the presence of posterior vitreous detachment [ 52 , 53 ].…”

Section: Key Retinal Biomarkersmentioning

confidence: 99%

“…Whilst the presence of PED at initial presentation has been associated with poor visual outcome [ 29 , 33 , 49 , 54 ], some reports state no significant association with the risk of developing macular/GA [ 39 ] whilst others report specifically the PED width does predict disease progression [ 55 ]. Conversely, post-hoc analysis of the EXCITE and VIEW studies reveal that PED does not significantly predict BCVA gains at 12 months [ 37 , 38 ].…”

Section: Key Retinal Biomarkersmentioning

confidence: 99%

Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review

Hanson

Airody

Sivaprasad

et al. 2022

Eye

View full text Add to dashboard Cite

The aim of this systematic literature review is twofold, (1) detail the impact of retinal biomarkers identifiable via optical coherence tomography (OCT) on disease progression and response to treatment in neovascular age-related macular degeneration (nAMD) and (2) establish which biomarkers are currently identifiable by artificial intelligence (AI) models and the utilisation of this technology. Following the PRISMA guidelines, PubMed was searched for peer-reviewed publications dated between January 2016 and January 2022. Population: Patients diagnosed with nAMD with OCT imaging. Settings: Comparable settings to NHS hospitals. Study designs: Randomised controlled trials, prospective/retrospective cohort studies and review articles. From 228 articles, 130 were full-text reviewed, 50 were removed for falling outside the scope of this review with 10 added from the author’s inventory, resulting in the inclusion of 90 articles. From 9 biomarkers identified; intraretinal fluid (IRF), subretinal fluid, pigment epithelial detachment, subretinal hyperreflective material (SHRM), retinal pigmental epithelial (RPE) atrophy, drusen, outer retinal tabulation (ORT), hyperreflective foci (HF) and retinal thickness, 5 are considered pertinent to nAMD disease progression; IRF, SHRM, drusen, ORT and HF. A number of these biomarkers can be classified using current AI models. Significant retinal biomarkers pertinent to disease activity and progression in nAMD are identifiable via OCT; IRF being the most important in terms of the significant impact on visual outcome. Incorporating AI into ophthalmology practice is a promising advancement towards automated and reproducible analyses of OCT data with the ability to diagnose disease and predict future disease conversion.Systematic Review Registration: This review has been registered with PROSPERO (registration ID: CRD42021233200).

show abstract

Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome

Cited by 4 publications

References 33 publications

Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis

Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis

Detailed optical coherence tomography angiographic short‐term response of type 3 neovascularization to combined treatment with photodynamic therapy and intravitreal bevacizumab

Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review

Contact Info

Product

Resources

About